A young boy with Duchenne muscular dystrophy (DMD) participating in Pfizer’s phase 2 gene therapy trial has died, the pharma shared in a May 7 letter (PDF) cited by nonprofit Parent Project Muscular Dystrophy.
The boy had received Pfizer’s fordadistrogene movaparvovec, an investigational recombinant adeno-associated virus gene therapy, in early 2023, according to the letter.…

#dmd#pfizer#pdf#daylight#ciffreo#mikaeldolsten#phd#sareptatherapeutics